Soley emerges with $200M Series C and broad pipeline for ‘stress clock’

Zoomhoot - Aggregate Digital Content That Matters For You

​A nimble biotech has been quietly toiling away for five years on a drug discovery platform aimed at tweaking the biological stress clock to treat cancer, obesity, hair loss and neurodegenerative disorders.

Soley Therapeutics is …

Read More from Endpoints News

Leave a Reply

Discover more from ZoomHoot - The Important Information You Need

Subscribe now to keep reading and get access to the full archive.

Continue reading